Competitor observation re Synairgen27 Oct 2020 16:03
Published in New York this morning:
The Chief Executive Officer for BetterLife Pharma Inc. (OTCQB:BETRF) (CSE:BETR), an emerging biotechnology company currently preparing for clinical trials of AP-003, .. said ..
The Synairgen trials caused much excitement, strongly demonstrating that treatments using an interferon beta inhalation in COVID-19 patients significantly improved their condition and sped up recovery. BetterLife is due to start its clinical trials later this fall in Australia for AP-003, BetterLife’s inhaled human interferon alpha 2b, in patients with mild to moderate symptoms of COVID-19.